Contrast media agents allows radiologists to differentiate between the normal and abnormal conditions

Publisher: The Insight Partners

According to a new market research study titled ‘Contrast Media Agents Market to 2027 – Global Analysis and Forecasts by Type, Imaging Modality, Indication, Route of Administration and Geography. The global contrast media agents market is expected to reach US$ 6,860.6 Mn in 2027 from US$ 4,698.2 Mn in 2018. The market is estimated to grow with a CAGR of 4.0% from 2019-2027. The market is likely to grow due to the prominent use of the contrast media agents in the diagnosis of the cardiovascular diseases through X-ray and CT scan as primary diagnosis.

Contrast media agents are also known as contrast materials or contrast media. These are generally used for the radiology practices as these have abilities to improve quality or visualization of images inside the body. The images are produced by the x-rays, computed tomography (CT) scans, magnetic resonance (MR) imaging and ultrasound. The contrast media agents allows radiologists to differentiate between the normal and abnormal conditions. These agents or substances temporarily change the way when the x-rays or other imaging tools interact with the body and thus helps in creating a good quality of image.

Global contrast media agents market was segmented by type, imaging modality, indication and route of administration. The type segment was classified as iodinated contrast media, gadolinium based contrast media, barium-based contrast media, microbubble contrast media. Based on the imaging modality the market is classified as X-Ray/CT, magnetic resonance imaging and ultrasound. On the basis of indication the market is classified as cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, nephrological disorders. And based on the route of administration the market is divided into intravascular, oral and rectal.

The major players operating in the contrast media agents market, General Electric, Bayer AG, Bracco, Guerbet, Lanthus Medical Imaging Inc., nanoPET Pharma GmbH, Unijules Life Sciences Ltd., Magnus Health Management Pvt. Ltd, J. B Chemicals and Pharmaceutical Ltd and Jodas Expoim. among the others.